One of the world’s top genome science institutions—BGI in China—has partnered with one of the world’s top translational research centres—the Vancouver Prostate Centre (VPC)—to revolutionize cancer detection and treatment. BGI has provided about $1 million in new equipment to establish a joint research lab at the VPC—its first collaboration with a Canadian research institution. BGI’s advanced sequencing platforms are being used to sequence hundreds of tumours and tumour models. PC-TRIADD will help commercialize shared technologies and create new companies. One product could be a simple blood test that provides a non-invasive and patient-friendly method for detecting, monitoring and treating cancer.